Indivior PLC $INDV Holdings Raised by Royce & Associates LP

Royce & Associates LP lifted its stake in Indivior PLC (NASDAQ:INDV) by 24.9% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 307,857 shares of the company’s stock after purchasing an additional 61,333 shares during the quarter. Royce & Associates LP owned 0.25% of Indivior worth $11,046,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Indivior by 43.4% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 317,600 shares of the company’s stock worth $11,395,000 after buying an additional 96,177 shares during the period. Federated Hermes Inc. purchased a new stake in shares of Indivior in the 3rd quarter valued at approximately $8,120,000. Claret Asset Management Corp boosted its stake in Indivior by 5.4% in the 3rd quarter. Claret Asset Management Corp now owns 784,588 shares of the company’s stock worth $18,916,000 after purchasing an additional 40,306 shares during the period. Aberdeen Group plc acquired a new position in Indivior in the 3rd quarter worth approximately $3,875,000. Finally, Victory Capital Management Inc. purchased a new position in Indivior during the 3rd quarter worth approximately $19,437,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Trading Down 1.9%

Shares of Indivior stock opened at $37.11 on Thursday. The stock has a 50-day moving average price of $33.78 and a 200 day moving average price of $33.86. The company has a market cap of $4.52 billion, a P/E ratio of 19.03 and a beta of 0.90. Indivior PLC has a 1 year low of $11.83 and a 1 year high of $41.00.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 earnings per share (EPS) for the quarter. The firm had revenue of $317.00 million during the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%. On average, equities analysts forecast that Indivior PLC will post 3.35 earnings per share for the current fiscal year.

Analyst Ratings Changes

INDV has been the topic of several research analyst reports. Weiss Ratings cut shares of Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 16th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $39.33.

Insider Transactions at Indivior

In related news, Director Stuart A. Kingsley acquired 940 shares of the stock in a transaction dated Friday, March 6th. The shares were acquired at an average price of $31.86 per share, with a total value of $29,948.40. Following the acquisition, the director owned 5,582 shares in the company, valued at approximately $177,842.52. The trade was a 20.25% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.74% of the company’s stock.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.